Loading...
Investigators at the 2018 Gastrointestinal Cancers Symposium, held January 18–20 in San Francisco, reported key advances in GI cancer research. NEJM Journal Watch Oncology and Hematology associate editor Dr. David Ilson was on hand to summarize the latest findings in esophagogastric, hepatocellular, biliary, and colorectal cancers. Abstracts from the symposium can be found in the meeting library.
Fuchs and colleagues presented results from the industry-sponsored, multicenter, randomized, double-blind, placebo-controlled RAINFALL trial (abstract 5), which compared first-line capecitabine and cisplatin chemotherapy with or without ramucirumab in 645 patients with HER2-negative metastatic gastric or gastroe…